I[NTRODUCTION]{.smallcaps} {#sec1-1}
==========================

Adrenal incidentalomas (AIs) are defined as adrenal mass lesions \>1 cm in diameter, discovered incidentally during investigation for conditions unrelated to adrenal disease. These incidentally discovered adrenal masses may be hormonally active or nonfunctioning and malignant or benign; the need for any treatment depends on the nature of the mass.

A growing body of evidence, both clinical and experimental, indicates that hormone-secreting AIs are associated with several components of metabolic syndrome, such as hypertension (HTN), atherogenic dyslipidemia, increased thrombogenicity, impaired glucose tolerance, insulin resistance, fatty liver disease, and abdominal obesity, through the effects of excessive adrenal hormones on various metabolic pathways.\[[@ref1][@ref2][@ref3]\] A similar association has been found in subclinical autonomous cortisol-secreting AIs and, paradoxically, nonfunctioning AIs, adding a new dimension to the clinical management and follow-up of these patients.\[[@ref4]\]

It has been suggested that patients with AI meet the criteria for the metabolic syndrome and that hyperinsulinemia is a major factor promoting tumor growth.\[[@ref5]\] According to the modified National Cholesterol Education Program criteria,\[[@ref6]\] the presence of any three of the five factors is required for a diagnosis of metabolic syndrome: abdominal obesity, hypertriglyceridemia (triglycerides ≥1.7 mmol/L); low high-density lipoprotein (HDL) (cholesterol ≤1.03 mmol/L for men and ≤1.29 mmol/L for women); elevated blood pressure (systolic blood pressure ≥130 mmHg and/or diastolic blood pressure ≥85 mmHg or current use of antihypertensive drugs); impaired fasting glucose (fasting plasma glucose ≥ 5.6 mmol/L).

Subclinical Cushing\'s syndrome (SCS) is the most frequent hormonal abnormality detected in patients with AI with wide variation in prevalence (5--47%) and the issue of subtle cortisol secretion by AIs is among the most controversial issues in endocrine practice. It has been hypothesized that subtle cortisol overproduction in subjects with AI may impact on carbohydrate metabolism.\[[@ref7]\] Comparison of groups of patients has generally revealed modest increases in body mass index (BMI), HTN, reduced insulin sensitivity, glucose intolerance or frank diabetes, adverse cardiovascular risk profile, and osteopenia/osteoporosis in patients with SCS compared to controls; however, most of the studies suffer to a degree from referral bias.\[[@ref8][@ref9]\]

Nonfunctioning AIs paradoxically have been recently implicated to predispose to metabolic syndrome and increasing evidence supports an association between nonfunctioning AIs and obesity, HTN, hyperglycemia, dyslipidemia, and insulin resistance.\[[@ref1][@ref7][@ref10][@ref11][@ref12][@ref13]\] This relationship appears to be theoretically inexplicable, as nonfunctioning AIs usually remain inactive; the cause--effect relationship and the underlying mechanisms have not been conclusively delineated and remain to be further elucidated.

Improvement in certain metabolic parameters has also been observed after unilateral adrenalectomy in patients with AIs. The aim of this systematic review is to advance the understanding of the association between nonfunctioning and subclinical autonomous cortisol secreting AIs and components of metabolic syndrome and the long-term clinical implications including surgical outcome, in order to appropriately address the management issues and to formulate suggestions for future research.

M[ETHODS]{.smallcaps} {#sec1-2}
=====================

Search strategy {#sec2-1}
---------------

A systematic search was performed for English language articles using MEDLINE, Cochrane Controlled Trials Register (1960--2005), and EMBASE (1991--2005). The literature was searched for the period from each database\'s earliest inception up to June 2018. In addition, the reference lists of the retrieved articles were examined to identify additional eligible studies. Combinations of keywords were used including "adrenal incidentalomas" or "adrenal mass," "subclinical Cushing\'s syndrome" or "preclinical Cushing\'s syndrome" or "autonomous cortisol secretion", "nonfunctioning adrenal incidentalomas" in combination with "metabolic syndrome", or "cardiometabolic" or "cardiovascular risk", or "insulin resistance" in the title or the abstract. The review was conducted in line with the preferred reporting items for systematic reviews and meta-analysis (PRISMA) statement.\[[@ref14]\]

Inclusion and exclusion criteria {#sec2-2}
--------------------------------

Original retrospective, prospective, or cross-sectional studies which analyzed patients with nonfunctioning and/or subclinical cortisol secreting AIs based on their biochemical profile reporting at least two components of metabolic syndrome (diabetes, impaired glucose tolerance, fasting hyperinsulinemia, dyslipidemia, HTN, and obesity/central adiposity) and the results of adrenalectomy and/or conservative management on these outcomes were included.

Studies without biochemically confirmed subclinical hypercortisolism and studies reporting only preoperative data or insufficient postoperative data were excluded from the systematic review, as were case reports and series including fewer than ten operated patients. Data quoted as unpublished or derived from abstracts were not used in the systematic review. The patients in the studies were classified into two groups: nonfunctioning AIs and subclinical cortisol secreting AIs. Nonfunctioning AI was defined as a subgroup of AI where the possibility of profound or even subclinical adrenal hormone excess was ruled out based on a comprehensive endocrine evaluation. Subclinical cortisol secreting AI was defined as a subgroup of AI with an abnormal response to standard tests of hypothalamic--pituitary--adrenal (HPA) axis function.

A predesigned data extraction form was used to collect data from the eligible studies. All variables were listed for which data were sought and information was extracted from each study including: 1) first author\'s last name, country, study design, number of participants; 2) age range and gender of study participants; 3) endocrine tests performed for autonomous cortisol secretion; 4) AI category: subclinical autonomous cortisol secreting or non-functioning; 5) outcome measures including, a) prevalence of components of metabolic syndrome in subclinical cortisol secreting AIs and nonfunctioning AIs, b) cardiometabolic outcomes of conservative management and adrenalectomy.

Methodological quality and risk of bias assessment {#sec2-3}
--------------------------------------------------

NIH quality assessment tool for observational cohort and cross-sectional studies was used to assess the risk of bias. It is based on the key concepts for evaluating the internal validity of a study; the critical assessments are made separately and are divided into 14 set of questions.\[[@ref15]\]

R[ESULTS]{.smallcaps} {#sec1-3}
=====================

The literature search yielded 65 publications in total. After screening abstracts for relevance, 36 full-text articles were assessed for eligibility and after applying the inclusion/exclusion criteria, 18 studies were included in the systematic review. Quantitative meta-analysis was not performed owing to significant clinical heterogeneity among the studies. A flow chart of this process is presented in [Figure 1](#F1){ref-type="fig"}.

![PRISMA flowchart of study selection process](IJEM-23-332-g001){#F1}

A total of 15 cohort studies (5 prospective and 10 retrospective), 1 randomized controlled trial (RCT), and 2 cross-sectional studies were included in the systematic review. Studies were mostly from European centers; 9 of the studies originated from Italy,\[[@ref2][@ref16][@ref17][@ref18][@ref19][@ref20][@ref21][@ref22][@ref23]\] 4 from Japan,\[[@ref24][@ref25][@ref26][@ref27]\] 2 from Greece,\[[@ref28][@ref29]\] and 1 each from Turkey,\[[@ref30]\] Hungary,\[[@ref31]\] and Korea.\[[@ref32]\] The studies were published between 2002 and 2017. They involved in total 1772 patients with AI. Of these, 1028 (58%) had nonfunctioning AI, while 500 (28.2%) had SCS. The main characteristics and demographics of the studies and outcome definitions are presented in Tables [1](#T1){ref-type="table"} and [2](#T2){ref-type="table"}, respectively.

###### 

Study characteristics and baseline demographics

  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Study                                   Study size (*n*)   Study design                  Country of origin   Age of participants (years)                        Sex of participants   Types of AI and number                     Duration of follow up                                             Cardiometabolic outcomes assessed
  --------------------------------------- ------------------ ----------------------------- ------------------- -------------------------------------------------- --------------------- ------------------------------------------ ----------------------------------------------------------------- -----------------------------------
  Giordano *et al*. 2010\[[@ref18]\]      118                Cohort prospective            Italy               62.4±0.9                                           77 F\                 NFA 10\                                    1-10 years (median 3 years)                                       Obese/overweight\
                                                                                                                                                                  47 M                  SCS 16                                                                                                       HTN dyslipidemia\
                                                                                                                                                                                                                                                                                                     IFG/IGT/T2DM

  Vassilatou *et al*. 2009\[[@ref29]\]    77                 Cohort prospective            Greece              57.1±10.9                                          55 F\                 NFA 57\                                    12-154 months (median 60 months)                                  Obese/overweight hypertension\
                                                                                                                                                                  22 M                  SCS 20                                                                                                       T2DM

  Di Dalmazi *et al*. 2012\[[@ref17]\]    348                Cross sectional               Italy               60.3±10.9\                                         127 F\                NFA 20\                                    No follow up                                                      HTN\
                                                                                                               NFA 67.3±8.3\                                      76 M\                 SCS 19\                                                                                                      DM\
                                                                                                               SCS                                                NFA\                  Intermediate phenotypes 126                                                                                  CHD\
                                                                                                                                                                  11 F\                                                                                                                              Stroke
                                                                                                                                                                  8 M\                                                                                                                               
                                                                                                                                                                  SCS                                                                                                                                

  Erbil *et al*. 2006\[[@ref30]\]         39                 Cohort prospective            Turkey              57±24\                                             10 F\                 SCS 1\                                     1 year post op (details NA)                                       Obesit\
                                                                                                               SCS 43±12 CS                                       1 M\                  CS 28                                                                                                        HTN\
                                                                                                                                                                  SCS\                                                                                                                               T2DM Dyslipidaemia
                                                                                                                                                                  26 F\                                                                                                                              
                                                                                                                                                                  2 M\                                                                                                                               
                                                                                                                                                                  CS                                                                                                                                 

  Toniato *et al*. 2009\[[@ref23]\]       45                 Randomised prospective        Italy               63±4.1\                                            11 F\                 SCS operated 23\                           Mean 7.7 years (range 2-17 years)                                 HTN\
                                                                                                               SCS operated\                                      12 M\                 SCS Conservative 22                                                                                          DM\
                                                                                                               64±1.8\                                            SCS operated\                                                                                                                      Obesity\
                                                                                                               SCS conservative                                   12 F\                                                                                                                              Hypercholesterolemia
                                                                                                                                                                  10 M\                                                                                                                              
                                                                                                                                                                  SCS conservative                                                                                                                   

  Chiodini *et al*. 2010\[[@ref16]\]      108                Cohort retrospective          Italy               54.8±11.6- SCS operated\                           33 F\                 SCS 41 NFA 67                              At least 18 months                                                HTN DM Obesity Dyslipidaemia
                                                                                                               64.4±10.1 SCS conservative\                        8 M\                                                                                                                               
                                                                                                               57.1±10.9 NFA operated 61.1±9.8 NFA conservative   SCS\                                                                                                                               
                                                                                                                                                                  47 F\                                                                                                                              
                                                                                                                                                                  20 F\                                                                                                                              
                                                                                                                                                                  NFA                                                                                                                                

  Morelli *et al*. 2014\[[@ref20]\]       206                Cohort retrospective          Italy               58.5±10.1 NFA\                                     119 F\                NFA 167\                                   At least 5 years                                                  HTN\
                                                                                                               62.2±11 SCS                                        48 M\                 SCS 39                                                                                                       DM\
                                                                                                                                                                  NFA\                                                                                                                               Obesity dyslipidemia
                                                                                                                                                                  25 F\                                                                                                                              
                                                                                                                                                                  14 M\                                                                                                                              
                                                                                                                                                                  SCS                                                                                                                                

  Iacobone *et al*. 2012\[[@ref19]\]      35                 Cohort prospective            Italy               Median 57 (range 36-78) SCS operated\              12 M\                 SCS operated 20\                           Mean 54±34 months\                                                HTN\
                                                                                                               58 (range 39-75) SCS conservative                  8 F\                  SCS conservative 15                        SCS operated 56±37 months SCS conservative                        DM dyslipidemia\
                                                                                                                                                                  SCS operated\                                                                                                                      Abnormal\
                                                                                                                                                                  8 M\                                                                                                                               BMI (overweight and obese)
                                                                                                                                                                  7 F\                                                                                                                               
                                                                                                                                                                  SCS conservative                                                                                                                   

  Maehana *et al*. 2012\[[@ref25]\]       73                 Cohort prospective            Japan               Mean\                                              35 M\                 NFA 60\                                    Median 51.2 months (range 6.0-171.9 months) NFA 11.7 months SCS   HTN\
                                                                                                               60 (range 32-81) NFA\                              25 F\                 SCS 13                                                                                                       DM dyslipidemia
                                                                                                               56 (range 31-72) SCS                               NFA\                                                                                                                               
                                                                                                                                                                  5 M\                                                                                                                               
                                                                                                                                                                  8 F\                                                                                                                               
                                                                                                                                                                  SCS                                                                                                                                

  Perysinakis *et al*. 2013\[[@ref28]\]   29                 Cohort retrospective          Greece              Mean 54 (range 31-68)                              8 M\                  SCS operated 29                            Mean 77 months                                                    HTN\
                                                                                                                                                                  21 F                                                                                                                               DM obesity

  Raffaeli *et al*. 2017\[[@ref22]\]      29                 Cohort retrospective          Italy               57.3±12.5 (range 30-76)                            7 M\                  SCS operated 29 (23 followed up post op)   51.0±24.0 months (range 11-90 months)                             HTN\
                                                                                                                                                                  22 F                                                                                                                               DM obesity

  Kawate *et al*. 2014\[[@ref24]\]        27                 Cohort retrospective          Japan               55.3±9.4 SCS operated 66.3±8.8 SCS conservative    2 M\                  SCS operated 15\                           Median 5.3 years                                                  HTN\
                                                                                                                                                                  13 F\                 SCS conservative 12                                                                                          DM obesity dyslipiemia
                                                                                                                                                                  SCS operated\                                                                                                                      
                                                                                                                                                                  6 M\                                                                                                                               
                                                                                                                                                                  6 F\                                                                                                                               
                                                                                                                                                                  SCS conservative                                                                                                                   

  Miyazato *et al*. 2011\[[@ref26]\]      114                Cohort retrospective          Japan               Median 58 (range 54-77)\                           21 M\                 SCS 55\                                    Median 2.9 years range 1-16 years                                 HTN\
                                                                                                               SCS 46 (range 20-65) CS                            34 F\                 CS 59                                                                                                        DM\
                                                                                                                                                                  SCS\                                                                                                                               BMI\
                                                                                                                                                                  8 M\                                                                                                                               Dyslipidemia
                                                                                                                                                                  51 F\                                                                                                                              
                                                                                                                                                                  CS                                                                                                                                 

  Petramala *et al*. 2017\[[@ref21]\]     70                 Cohort retrospective          Italy               61.9±8.4                                           52 M\                 SCS operated 26\                           Mean 12 months (range 9-15 months)                                HTN\
                                                                                                                                                                  18 F                  SCS conservative 44                                                                                          Obesity\
                                                                                                                                                                                                                                                                                                     DM\
                                                                                                                                                                                                                                                                                                     Metabolic syndrome

  Sereg *et al*. 2009\[[@ref31]\]         125                Cohort retrospective cohort   Hungary             51.8±9.9                                           29 M\                 NFA operated 47\                           Mean 9.1 years (range 5-16 years)                                 HTN\
                                                                                                                                                                  96 F                  NFA conservative 78                                                                                          DM/IGT\
                                                                                                                                                                                                                                                                                                     Obesity\
                                                                                                                                                                                                                                                                                                     Dyslipidemia

  Tsuiki *et al*. 2008\[[@ref27]\]        20                 Cohort retrospective          Japan               Median 59.7 (range 43-74)                          6 M\                  SCS operated 10\                           7-19 months (average 13±3.8 months)\                              HTN\
                                                                                                                                                                  14 F                  SCS conservative 12                        SCS operated 15-69 months (average 27±15.2 months)\               Impaired glucose metabolism\
                                                                                                                                                                                                                                   SCS conservative                                                  Dyslipidemia Obesity

  Terzolo *et al*. 2002\[[@ref2]\]        41                 Cross sectional               Italy               Mean 54.0±10.7 (range 19-69)                       NA                    NFA 29\                                    No follow up                                                      HTN\
                                                                                                                                                                                        SCS 12                                                                                                       Impaired glucose metabolism\
                                                                                                                                                                                                                                                                                                     Dyslipidaemia\
                                                                                                                                                                                                                                                                                                     Raised BMI

  Kim *et al*. 2014\[[@ref32]\]           268                Cohort retrospective          Korea               Mean 55.8±15.8 (range 15-90)                       138M\                 NFA 218\                                   No follow up                                                      HTN\
                                                                                                                                                                  130 F                 SCS 19\                                                                                                      DM\
                                                                                                                                                                                        Other AIs 31                                                                                                 BMI\
                                                                                                                                                                                                                                                                                                     Hypercholesterolemia
  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

SCS: Subclinical cushing's syndrome, CS: Cushing's syndrome, NFA: Nonfunctioning adrenal adenoma, DM: Diabetes mellitus, IFG: Impaired fasting glucose, IGT: Impaired glucose tolerance, HTN: Hypertension, BMI: Body mass index, CHD: Coronary heart disease, NA: Not available, AIs: Adrenal incidentalomas

###### 

Definitions of clinical outcomes

  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
                                     Obesity definition                                      HTN definition (mmHg)                                                                                 DM definition                                                                                                     Dyslipidemia definition                                                                                                     Others
  ---------------------------------- ------------------------------------------------------- ----------------------------------------------------------------------------------------------------- ----------------------------------------------------------------------------------------------------------------- --------------------------------------------------------------------------------------------------------------------------- -----------------------------------------------------------------
  Giordano *et al*.\[[@ref18]\]      Overweight/obesity: BMI \>25 kg/m^2^                    BP \>125/80                                                                                           IGT: 2 h post OGTT glucose 140-200 mg/dl\                                                                         Triglycerides \>150 mg/dl\                                                                                                  
                                                                                                                                                                                                   Diabetes: fasting glucose 126 mg/dl                                                                               Total cholesterol \>240 mg/dl                                                                                               

  Vassilatou *et al*.\[[@ref29]\]    NA                                                      NA                                                                                                    NA                                                                                                                NA                                                                                                                          

  Di Dalmazi *et al*.\[[@ref17]\]    Obesity not in outcome                                  SBP ≥140 and/or DBP ≥90 measured on at least 2 separate occasions and/or antihypertensive treatment   T2DM: OGTT as per the ADA position statement\[[@ref33]\] and/or treatment with antidiabetic drugs                 Total cholesterol ≥200 mg/dl and/or\                                                                                        
                                                                                                                                                                                                                                                                                                                     Triglycerides ≥150 mg/dl                                                                                                    

  Erbil *et al*.\[[@ref30]\]         Obesity: BMI \>30 kg/m^2^                               BP \>130/85 or antihypertensive treatment                                                             IFG: fasting glucose \>110 mg/dl DM: fasting glucose \>126 mg/dl or treatment with antidiabetic drugs             Triglycerides \>150 mg/dl HDL \<40 mg/dl in men HDL \<50 mg/dl in women                                                     

  Toniato *et al*.\[[@ref23]\]       Overweight: BMI 25-30 kg/m^2^ Obese: BMI \>30 kg/m^2^   SBP \>150 and DBP \>90                                                                                IFG: fasting glucose \>110 mg/dl\                                                                                 Triglycerides \>150 mg/dl\                                                                                                  
                                                                                                                                                                                                   DM: fasting glucose \>126 mg/dl or treatment with antidiabetic drugs                                              HDL \<40 mg/dl in men\                                                                                                      
                                                                                                                                                                                                                                                                                                                     HDL \<50 mg/dl in women                                                                                                     

  Morelli *et al*.\[[@ref20]\]       NA                                                      SBP ≥140 and/or DBP ≥90 and/or antihypertensive treatment                                             WHO criteria\[[@ref34]\]                                                                                          Triglycerides ≥150 mg/dl or HDL \<40 mg/dl in men\                                                                          
                                                                                                                                                                                                                                                                                                                     HDL \<50 mg/dl in women or on anti-dyslipidemic treatment                                                                   

  Iacobone *et al*.\[[@ref19]\]      Overweight: BMI 25-29.9 kg/m^2^\                        SBP ≥140\                                                                                             IGT: FPG \>110 mg/dl\                                                                                             Triglycerides ≥150 mg/dl\                                                                                                   
                                     Obese: BMI ≥30 kg/m^2^                                  DBP ≥90 or antihypertensive treatment                                                                 DM: FPG \>126 mg/dl or treatment with antidiabetic drugs                                                          HDL \<40 mg/dl in men\                                                                                                      
                                                                                                                                                                                                                                                                                                                     HDL \<50 mg/dl in women Patients on anti-dyslipidemic treatment                                                             

  Maehana *et al*.\[[@ref25]\]       NA                                                      NA                                                                                                    NA                                                                                                                NA                                                                                                                          

  Perysinakis *et al*.\[[@ref28]\]   Obesity: BMI ≥30 kg/m^2^                                SBP ≥135\                                                                                             DM: WHO criteria of\                                                                                                                                                                                                                          
                                                                                             DBP ≥85 or antihypertensive treatment                                                                 FPG \>126 or treatment with antidiabetic drugs                                                                                                                                                                                                

  Raffaelli *et al*.\[[@ref22]\]     NA                                                      NA                                                                                                    NA                                                                                                                NA                                                                                                                          

  Kawate *et al*.\[[@ref24]\]        Obesity: BMI≥25 kg/m^2^                                 SBP ≥140\                                                                                             DM: FPG ≥126 mg/dl and/or random glucose≥200 mg/dl and/or HbA1c ≥6.5% and/or treatment with antidiabetic drugs\   Total cholesterol ≥220 mg/dl and/or LDL ≥140 mg/dl and/or HDL \<40 mg/dl and/or\                                            
                                                                                             DBP ≥90 or antihypertensive treatment                                                                 IGT: FBS ≥110 mg/dl and/or random glucose 140-199 mg/dl                                                           Triglycerides ≥150 mg/dl\                                                                                                   
                                                                                                                                                                                                                                                                                                                     Treatment with lipid-lowering medication                                                                                    

  Miyazato *et al*.\[[@ref26]\]      Obesity: BMI ≥25 kg/m^2^                                SBP \>150\                                                                                            IGT: FPG ≥110 mg/dl\                                                                                              Total cholesterol 220 mg/dl,\                                                                                               
                                                                                             DBP \>90                                                                                              DM: FPG ≥126 mg/dl or treatment with antidiabetic drugs                                                           Triglycerides ≥172 mg/dl or statin use                                                                                      

  Petramala *et al*.\[[@ref21]\]     NA                                                      NA                                                                                                    NA                                                                                                                NA                                                                                                                          Metabolic syndrome defined by ATP III-NCEP criteria\[[@ref35]\]

  Sereg *et al*.\[[@ref31]\]         NA                                                      BP persistently \>140/90 mmHg or antihypertensive treatment                                           Previous definitive diagnosis of DM and treatment with antidiabetic drugs\                                        Total cholesterol \>5.2 mmol/l LDL \>2.6 mmol/l or Triglycerides \>1.7 mmol/l or treatment with lipid-lowering medication   
                                                                                                                                                                                                   DM: OGTT FPG \>7.0 mmol/l, glucose response after 120 min ≥11.1 mmol/l\                                                                                                                                                                       
                                                                                                                                                                                                   IGT: OGTT glucose response after 120 min 7.8-11.0 mmol/l                                                                                                                                                                                      

  Tsuiki *et al*.\[[@ref27]\]        Obesity: BMI ≥25 kg/m^2^                                SBP \>140 and/or DBP \>90                                                                             DM: FPG \>126 mg/dl or 2 h plasma glucose \>200 mg/dl\                                                            Total cholesterol \>220 mg/dl                                                                                               
                                                                                                                                                                                                   IGT: FPG 110-125 and/or 2 h plasma glucose 140-199 mg/dl on 75 g OGTT                                                                                                                                                                         

  Terzolo *et al*.\[[@ref2]\]        No criteria; absolute values of BMI                     No criteria; absolute values of SBP and DBP                                                           No criteria; absolute values of 2 hour glucose and insulin sensitivity index                                      No criteria; absolute values of Triglycerides, total and HDL cholesterol                                                    

  Kim *et al*.\[[@ref32]\]           No criteria; absolute values of BMI                     Prior diagnosis of HTN or antihypertensive treatment\                                                 Prior diagnosis of DM or treatment with oral hypoglycaemic agents\                                                No criteria; absolute values of total cholesterol                                                                           
                                                                                             SBP ≥140 or DBP ≥90                                                                                   FPG ≥126 mg/dl or\                                                                                                                                                                                                                            
                                                                                                                                                                                                   HbA1c ≥6.5%                                                                                                                                                                                                                                   
  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

OGTT: Oral glucose tolerance test, IGT: Impaired glucose tolerance, FPG: Fasting plasma glucose, SBP: Systolic blood pressure, DBP: Diastolic blood pressure, ADA: American diabetes association, WHO: World health organisation NA: Not available

Diagnostic criteria or definition of SCS were heterogeneous in the studies, as presented in [Table 3](#T3){ref-type="table"}. They were mostly based on high morning cortisol concentrations after dexamethasone suppression test (DST) combined with at least one other test of HPA axis function.

###### 

Definitions of subclinical Cushing's syndrome

  Study                              Criteria for SCS diagnosis
  ---------------------------------- -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Giordano *et al*.\[[@ref18]\]      Absence of clinical signs or symptoms of cortisol excess, and Post 1 mg overnight DST cortisol ≥1.8 µg/dl (50 nmol/l) plus one other abnormal test of HPA axis: post LDDST cortisol ≥1.8 µg/dl, low ACTH, elevated midnight salivary cortisol, high UFC
  Vassilatou *et al*. \[[@ref29]\]   Absence of clinical signs of cortisol excess, and Post LDDST cortisol ≥50 nmol/l plus at least one other abnormal test of HPA axis: low ACTH, abnormal cortisol rhythm (plasma cortisol at 24·00: 8·00% ratio \>50%), high UFC, low for age DHEAS
  Di Dalmazi *et al*. \[[@ref17]\]   Absence of clinical signs or symptoms specific to overt CS, and For SCS- post 1 mg overnight DST cortisol \>138 nmol/l with no other additional tests For intermediate phenotypes- overnight DST cortisol 50-138 nmol/l plus one other abnormal test (low ACTH and high 24 h UFC)
  Erbil *et al*. \[[@ref30]\]        No symptoms directly attributed to the disease, and Both LDDST and HDDST failed to suppress cortisol \<3 µg/dl
  Toniato *et al*.\[[@ref23]\]       No clinical signs of hormone excess, and 1 mg overnight DST \>2.5 µg/dl and 1 other HPA axis functional alteration
  Morelli *et al*.\[[@ref20]\]       Absence of signs of overt hypercortisolism, and Post 1 mg overnight DST cortisol levels \>5 µg/dL (138 nmol/L) or 2 of the 3 abnormalities of HPA axis: suppressed ACTH, increased UFC, and 1 mg-DST cortisol levels \>3.0 µg/dL (83 nmol/L)
  Iacobone *et al*.\[[@ref19]\]      Absence of clinical features of CS, and Post 1 mg overnight DST cortisol \>5 µg/dL, morning ACTH suppressed and increased 24 h UFC
  Maehana *et al*.\[[@ref25]\]       Absence of clinical features of CS, and Normal basal cortisol, post 1 mg ODST cortisol \>3 µg/dl plus one of: suppressed ACTH, loss of cortisol circadian rhythm, low DHEAS, or unilateral visualisation on adrenocortical scintigraphy
  Perysinakis *et al*.\[[@ref28]\]   Absence of clinical signs of cortisol excess, and Post LDDST Cortisol ≥1.8 µg/dl plus at least one other abnormal test of HPA axis: suppressed ACTH, raised 24 hours UFC, midnight cortisol/morning cortisol percent ratio \>50%.
  Raffaelli *et al*.\[[@ref22]\]     Absence of clinical features of overt CS, and Post 1 mg overnight DST cortisol \>18 ng/mL plus at least 2 criteria of the following: suppressed basal ACTH levels, high UFC, altered circadian cortisol rhythm & unilateral uptake on adrenocortical scintigraphy
  Kawate *et al*.\[[@ref24]\]        Absence of typical CS features, and Post 1 mg overnight DST cortisol \>1.8 µg/dl, low morning ACTH, increased uptake on adrenal scintigraphy, no diurnal changes in cortisol level and low DHEAS.
  Miyazato *et al*.\[[@ref26]\]      Diagnosed as SCS by the endocrinology team, criteria not mentioned
  Petramala *et al*.\[[@ref21]\]     Absent overt clinical signs of hypercortisolism, and 2 or more HPA axis function test abnormality: High UFC, morning cortisol \>1.8 µg/dl after 1 mg overnight DST, morning ACTH levels suppressed
  Tsuiki *et al*.\[[@ref27]\]        Lack of characteristic features of CS, and Normal basal cortisol, cortisol \>3 µg/dl after 1 mg overnight DST and cortisol \>1 µg/dl after 8 mg overnight DST plus at least one of the additional criteria: suppressed basal ACTH levels, altered circadian cortisol rhythm, decreased DHEAS & unilateral uptake on adrenocortical scintigraphy
  Terzolo *et al*.\[[@ref2]\]        Absence of classical clinical features of CS, and Two of the following criteria: Elevated UFC, failure of cortisol to suppress to \<138 nmol/l after 1 mg overnight DST, suppressed ACTH concentrations, and disturbed cortisol circadian rhythm
  Kim *et al*.\[[@ref32]\]           Lack of specific symptoms or signs of CS, and Elevated 24 hUFC and low morning ACTH (LDDST to increase diagnostic specificity of CS, but not a criteria for SCS in the study)

CS: Cushing's syndrome, ACTH: Adrenocorticotropic hormone, SCS: Subclinical Cushing's syndrome, UFC: Urinary free cortisol, DST: Dexamethasone suppression test, DHEAS: Dehydroepiandrosterone sulfate, LDDST: Low dose dexamethasone suppression test

All the studies included in the systematic review had patients with subclinical cortisol secreting AIs and half of the studies had patients with nonfunctioning AIs. The clinical characteristics at baseline and outcome on follow-up in patients with SCS are presented in [Table 4](#T4){ref-type="table"}.

###### 

SCS and cardiometabolic outcomes

  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Study                              Patients with SCS (*n*)   Adrenalectomy (*n*)   Conservative management (*n*)   Metabolic parameters at baseline              Metabolic parameters at follow up                                                                                                                             
  ---------------------------------- ------------------------- --------------------- ------------------------------- --------------------------------------------- --------------------------------------------- --------------------------------------------------------------------------------------------------------------- --------------------------------------------------------------------------------------------
  Toniato *et al*.\[[@ref23]\]       45                        23                    22                              DM 8 (34.8%)\                                 DM 6 (27.3%)\                                 HTN improved 7 (38.9%), normalised 5 (27.8%) *P*=0.046 DM improved 3 (37.5%), normalised 2 (25%) *P*=0.619\     DM worsened 2 (9%)\
                                                                                                                     HTN 18 (78.3%)\                               HTN 15 (68.2%) Obesity 6 (27.3%)\             Hypercholesterolemia normalised 3 (37.5%) *P*=0.619\                                                            HTN worsened 5 (22.7%)\
                                                                                                                     Obesity 6 (26.1%)\                            Hypercholesterolemia 7 (31.8%)                BMI normalised 3 (50%) *P* value NA                                                                             Hypercholesterolemia worsened 3 (13.6%)\
                                                                                                                     Hypercholesterolemia 8 (34.8%)                                                                                                                                                                              Obesity NA

  Chiodini *et al*.\[[@ref16]\]      41                        16                    25                              Obesity 12 (48%)\                             Excluded from systematic review               Obesity *P*=0.05\                                                                                               Excluded from systematic review
                                                                                                                     HTN 14 (56%)\                                                                               HTN *P*\<0.001\                                                                                                 
                                                                                                                     DM 7 (28%)\                                                                                 DM *P*\<0.001\                                                                                                  
                                                                                                                     Dyslipidaemia 12 (48%)                                                                      Dyslipidaemia *P*=0.05                                                                                          

  Iacobone *et al*.\[[@ref19]\]      35                        15                    20                              Abnormal BMI (Obese + overweight) 15 (75%)\   Abnormal BMI (Obese + overweight) 12 (80%)\   BMI *P*=0.19\                                                                                                   BMI worsened 3/12 (25%)\
                                                                                                                     HTN 15 (75%)\                                 HTN 12 (80%)\                                 HTN *P*=0.002\                                                                                                  HTN worsened 3/12 (25%)\
                                                                                                                     DM &\                                         DM & IGT 6 (40%)\                             DM & IGT *P*=0.032\                                                                                             DM & IGT worsened 2/6 (33%)\
                                                                                                                     IGT 10 (50%)\                                 Dyslipidaemia 7 (46.7%)                       Dyslipidaemia *P*=0.47                                                                                          Dyslipidaemia no change
                                                                                                                     Dyslipidaemia 10 (50%)                                                                                                                                                                                      

  Kawate *et al*.\[[@ref24]\]        27                        15                    12                              HTN 10 (67%)\                                 HTN 6 (50%)\                                  Improvement: HTN 6 (67%)\                                                                                       Improvement: HTN 0 (0%)\
                                                                                                                     DM 5 (33%)\                                   DM 5 (42%)\                                   DM or IGT 3 (60%)\                                                                                              DM or IGT 1 (20%)\
                                                                                                                     Dyslipidaemia 8 (53%)\                        Dyslipidaemia 10 (83%)\                       Dyslipidaemia 1 (13%) *P* values NA                                                                             Dyslipidaemia 1 (10%) Worsening: HTN 4 (67%)\
                                                                                                                     Obesity 5 (33%)                               Obesity 5 (42%)                                                                                                                                               DM or IGT 2 (40%)\
                                                                                                                                                                                                                                                                                                                                 Dyslipidaemia 2 (20%)

  Petramala *et al*.\[[@ref21]\]     70                        26                    44                              HTN 85%\                                      HTN 63.1%\                                    HTN 58.82% *P*\<0.05\                                                                                           HTN 72.5% DM 38.5% Obesity 42.7% Metabolic syndrome 45% Low HDL 13% High Triglycerides 38%
                                                                                                                     DM 38%\                                       DM 25%\                                       DM 23.5% *P*=NS\                                                                                                
                                                                                                                     Obesity 53.8%\                                Obesity 33%\                                  Obesity 24.5% *P*\<0.05\                                                                                        
                                                                                                                     Metabolic syndrome 54%\                       Metabolic syndrome 39%\                       Metabolic syndrome 23% *P*\<0.05\                                                                               
                                                                                                                     Low HDL 27%\                                  Low HDL 11%\                                  Low HDL 11% P=NS\                                                                                               
                                                                                                                     High Triglycerides 34%                        High Triglyceride 34%                         High Triglycerides 27% *P*=NS                                                                                   

  Tsuiki *et al*.\[[@ref27]\]        20                        10                    12                              HTN 6 (60%)\                                  HTN 4 (33%)\                                  Improvement: HTN 5\                                                                                             Improvement: none\
                                                                                                                     Impaired glucose metabolism 9 (90%)\          Impaired glucose metabolism 6 (50%)\          Impaired glucose metabolism 2\                                                                                  HTN: 1 worsened; 1 developed HTN\
                                                                                                                     Dyslipidaemia 9 (90%)\                        Dyslipidaemia 6 (50%)\                        Dyslipidaemia 6\                                                                                                Impaired glucose metabolism: 1 worsened, 2 developed impaired glucose metabolism\
                                                                                                                     Obesity 3 (30%)                               Obesity 3 (25%)                               Obesity 0\                                                                                                      Dyslipidaemia: none worsened, 2 developed dyslipidaemia\
                                                                                                                                                                                                                 Prognosis of cardiovascular risks significantly better in the operated than the non-operated group *P*\<0.001   Obesity: none worsened, 2 developed obesity

  Maehana *et al*.\[[@ref25]\]       13                        12                    1 (refused)                     HTN 7 (58.3%)\                                \-                                            Improvement: HTN 5/7 (71.4%)\                                                                                   \-
                                                                                                                     DM 2 (16.6%)\                                                                               DM 2/2 (100%)\                                                                                                  
                                                                                                                     Dyslipidaemia 3 (25%)                                                                       Dyslipidaemia 2/3 (66.7%)                                                                                       

  Perysinakis *et al*.\[[@ref28]\]   29                        29                    0                               BMI \>27 14 (48.3%)\                          \-                                            Improvement: BMI 6/14 (42.9%)\                                                                                  \-
                                                                                                                     HTN 17 (58.6%)\                                                                             HTN 12/17 (70.6%)\                                                                                              
                                                                                                                     DM 12 (41.4%)                                                                               DM\|/IGT 5/12 (41.7%)                                                                                           

  Raffaelli *et al*.\[[@ref22]\]     27                        27                    0                               BMI 28.0±3.2 (24-37)\                         \-                                            Improvement: BMI *P*=0.75\                                                                                      \-
                                                                                                                     SBP 138.8±13.1 (120-160)\                                                                   SBP *P*=0.07\                                                                                                   
                                                                                                                     DBP 87.7±8.0 (75-100)\                                                                      DBP *P*=0.41 DM *P*\<0.05                                                                                       
                                                                                                                     Fasting glucose 132.7±17.8 (105-168)                                                                                                                                                                        

  Miyazato *et al*.\[[@ref26]\]      55                        55                    0                               HTN 33 (60%)\                                 \-                                            Improvement: HTN 6/33 (18.2%) *P*\<0.001\                                                                       \-
                                                                                                                     DM 17 (30.9%)\                                                                              DM 3/17 (17.7%) *P*=0.001 Dyslipidaemia 0 *P*=0.292                                                             
                                                                                                                     Dyslipidaemia 5 (9.1%)\                                                                                                                                                                                     
                                                                                                                     BMI \>25 20 (36.3%)                                                                                                                                                                                         

  Erbil *et al*.\[[@ref30]\]         11                        11                    0                               Obesity - 5 (55%)\                            \-                                            Improvement: Obesity 3 (60%) *P*=0.127\                                                                         \-
                                                                                                                     HTN 7 (63%)\                                                                                HTN 5 (71%) *P*=0.03\                                                                                           
                                                                                                                     DM 4 (36%)\                                                                                 DM 2 (33%) *P*=0.338\                                                                                           
                                                                                                                     Hypercholesterolemia 4 (36%)\                                                               Hypercholesterolemia 3 (75%) *P*=0.127\                                                                         
                                                                                                                     Hypertriglyceridemia 3 (27%)                                                                Hypertriglyceridemia 1 (33%) *P*=0.611                                                                          

  Vassilatou *et al*.\[[@ref29]\]    20                        0                     20                              \-                                            Mean BMI 30.1±4.6\                                                                                                                                            BMI NS\
                                                                                                                                                                   HTN 15 (75%)\                                                                                                                                                 HTN 16 (80%)\
                                                                                                                                                                   DM 4 (20%)                                                                                                                                                    DM 5 (25%)

  Morelli *et al*.\[[@ref20]\]       39                        0                     39                              \-                                            Obesity 13 (33.3%)\                           \-                                                                                                              Obesity 18 (46.2%)\
                                                                                                                                                                   HTN 26 (66.7%)\                                                                                                                                               HTN 34 (87.2%) *P*\<0.05\
                                                                                                                                                                   DM 13 (33.3%)\                                                                                                                                                DM 17 (43.6%)\
                                                                                                                                                                   Dyslipidaemia 21 (53.8%)                                                                                                                                      Dyslipidaemia 27 (69.2%)
  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Out of 18 studies included in the review, 9 had patients with nonfunctioning AIs, 3 of the studies had no follow-up data, so they were only used for comparison between SCS and nonfunctioning AIs at baseline.\[[@ref2][@ref17][@ref32]\] The clinical characteristics at baseline and outcome on follow-up in patients with nonfunctioning AIs are presented in [Table 5](#T5){ref-type="table"}.

###### 

Nonfunctioning AIs and cardiometabolic outcomes

  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Study                             Patients with non-functioning AI (*n*)   Adrenalectomy (*n*)   Conservative management (*n*)   Metabolic parameters at baseline   Metabolic parameters at follow up                                             
  --------------------------------- ---------------------------------------- --------------------- ------------------------------- ---------------------------------- ----------------------------------- ----------------------------------------- ------------------------------------------------------
  Giordano *et al*.\[[@ref18]\]     102                                      0                     102                                                                Obese/overweight 57 (55%)\                                                    Obese/overweight 57 (55%)\
                                                                                                                                                                      HTN 60 (58%)\                                                                 HTN 60 (58%)\
                                                                                                                                                                      Dyslipidaemia 24 (23%)\                                                       Dyslipidaemia 27 (26%)\
                                                                                                                                                                      IFG/IGT/DM 15 (15%)                                                           IFG/IGT/DM 22 (21%)

  Vassilatou *et al*.\[[@ref29]\]   57                                       0                     57                                                                 Mean BMI 30.1±4.6\                                                            BMI no significant change\
                                                                                                                                                                      HTN 32 (56%)\                                                                 HTN 36 (63%)\
                                                                                                                                                                      DM 13 (22.8%)                                                                 DM 15 (26.3%)

  Chiodini *et al*.\[[@ref16]\]     67                                       30                    37                              Obesity 8 (26.7%)\                                                     Improvement: Obesity 3 (10%)\             
                                                                                                                                   HTN 16 (53.3%)\                                                        HTN 9 (30%)\                              
                                                                                                                                   DM 3 (14.3%)\                                                          DM 3 (10%)\                               
                                                                                                                                   Dyslipidaemia 9 (30%)                                                  Dyslipidaemia 8 (26.7%)\                  
                                                                                                                                                                                                          Worsening: Obesity 6 (20%)\               
                                                                                                                                                                                                          HTN 4 (13.3%)\                            
                                                                                                                                                                                                          DM 1 (3.3%)\                              
                                                                                                                                                                                                          Dyslipidaemia 3 (10%)                     

  Morelli *et al*.\[[@ref20]\]      167                                      0                     167                                                                Obesity 46 (27.5%)\                                                           Obesity 54 (32.3%)\
                                                                                                                                                                      HTN 90 (53.9%)\                                                               HTN 105 (62.9%)\
                                                                                                                                                                      DM 28 (16.8%)\                                                                DM 37 (22.2%)\
                                                                                                                                                                      Dyslipidaemia 70 (41.9%)                                                      Dyslipidaemia 90 (53.9%) *P*\<0.05 for Dyslipidaemia

  Maehana *et al*.\[[@ref25]\]      60                                       21                    39                              HTN 5 (23.8%)\                                                         Improvement: HTN 1/5 (20%)\               
                                                                                                                                   DM 2 (9.5%)\                                                           DM 0/2 (0%)\                              
                                                                                                                                   Dyslipidaemia 1 (4.7%)                                                 Dyslipidaemia 0/1 (0%) *P* values NA      

  Sereg *et al*.\[[@ref31]\]        113                                      43                    70                              Obesity 27 (63%)\                  Obesity 29 (41%)\                   Obesity 26 (60%)\                         Obesity 30 (43%)\
                                                                                                                                   HTN 37 (86%)\                      HTN 56 (80%)\                       HTN 38 (88%)\                             HTN 63 (90%)\
                                                                                                                                   DM 4 (9%)\                         DM 19 (27%)\                        DM 18 (42%)\                              DM 36 (51%)\
                                                                                                                                   IGT 15 (35%)\                      IGT 11 (16%)\                       IGT 7 (16%)\                              IGT 4 (6%)\
                                                                                                                                   Dyslipidaemia 24 (56%)             Dyslipidaemia 42 (60%)              Dyslipidaemia 39 (91%)\                   Dyslipidaemia 54 (77%)\
                                                                                                                                                                                                          Worsening: Dyslipidaemia *P*\<0.0001\     Worsening: Dyslipidaemia *P*\<0.05\
                                                                                                                                                                                                          DM *P*\<0.001 IGT *P*\<0.05 Rest *P*=NS   DM *P*\<0.05 Rest *P*=NS
  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Six studies compared the prevalence of cardiometabolic risk factors in patients with nonfunctioning AIs and subclinical cortisol secreting AIs.\[[@ref2][@ref16][@ref17][@ref18][@ref29][@ref32]\] The comparison is presented in [Table 6](#T6){ref-type="table"}.

###### 

Comparison of prevalence of cardiometabolic risk factors between SCS and NFAI

  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
                                           Number of patients (*n*)   Obesity/overweight   HTN             DM                                                Dyslipidaemia                     Others
  ---------------------------------------- -------------------------- -------------------- --------------- ------------------------------------------------- --------------------------------- -------------------------------
  Giordano *et al*.\[[@ref18]\]            NFAI 102\                  *P*=NS               P=NS            *P*=NS                                            *P*=0.033                         
                                           SCS 16                                                                                                                                              

  Vassilatou *et al*.\[[@ref29]\]          NFAI 57\                   *P*=0.98 (NS)        *P*=0.10 (NS)   *P*=0.9 (NS)                                      NA                                
                                           SCS 20                                                                                                                                              

  Di Dalmazi *et al*.\[[@ref17]\]          NFAI 203\                  Not checked          NS              *P*\<0.01                                         Not checked                       CHD: *P*\<0.01 Stroke: *P*=NS
                                           SCS 19                                                                                                                                              

  Kim *et al*.\[[@ref32]\]                 NFAI 218\                  *P*=0.031            *P*=0.047       *P*=0.034                                         Total cholesterol: *P*=0.048\     
                                           SCS 19                                                                                                            LDL, HDL, Triglycerides: *P*=NS   

  Terzolo *et al*.\[[@ref2]\]              NFAI 29\                   *P*=NS               *P*=NS          2 h glucose: *P*=0.04\                            Triglycerides: *P*=0.006\         
                                           SCS 12                                                          Insulin sensitivity index: *P*=0.0001             Total cholesterol, HDL: *P*=NS    

  Chiodini *et al*.\[[@ref16]\]                                                                                                                                                                

   Operated SCS vs operated NFAI           NFAI 30\                   *P*\<0.01            *P*\<0.01       *P*\<0.01                                                                           
                                           SCS 25                                                                                                                                              

   Non operated SCS vs non operated NFAI   NFAI 37\                   *P*=NS               *P*=NS          *P*=0.05 \[worsened glycaemic control for SCS\]   *P*=NS                            
                                           SCS 16                                                                                                                                              
  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

SCS: Subclinical Cushing's syndrome, CS: Cushing's syndrome, NFAI: Nonfunctioning adrenal incidentaloma, HTN: Hypertension, CHD: Coronary heart disease, DM: Diabetes mellitus, OGTT: Oral glucose tolerance test, IGT: Impaired glucose tolerance, FPG: Fasting plasma glucose, SBP: Systolic blood pressure, DBP: Diastolic blood press, BMI: Body mass index, ADA: American Diabetes Association, WHO: World Health Organisation, NS: Not significant, NA: Not available

The systematic review demonstrated higher prevalence of HTN, impaired glucose metabolism, dyslipidemia, and raised BMI in patients with subclinical cortisol secreting AIs as compared to patients with nonfunctioning AI. In patients with SCS surgical intervention had a beneficial effect on blood pressure, glucometabolic control, and obesity when compared with conservative management. The results for lipid metabolism were equivocal. There was no significant improvement in cardiometabolic risk factors after adrenalectomy in patients with nonfunctioning AIs. Summary of the results is presented in [Table 7](#T7){ref-type="table"}.

###### 

Summary of results

                                                                        Subclinical cortisol secreting AI          Non-functioning AI
  --------------------------------------------------------------------- ------------------------------------------ -----------------------------------------------------------
  Baseline prevalence (range)                                                                                      
   DM/IGT                                                               16.6-90%                                   9-27%
   HTN                                                                  33-85%                                     24-86%
   Dyslipidaemia                                                        9-90%                                      5-60%
   Obesity/overweight                                                   25-80%                                     27-63%
  Number of patients who had surgery                                    Range 10-55 Mean 22                        Range 21-43
  Significant improvement in surgically treated group (*P*\<0.05)                                                  
   DM/IGT                                                               More than half of the studies              None; significant worsening in one study
   HTN                                                                  Most studies                               None
   Dyslipidemia                                                         Few studies                                None; significant worsening in one study
   Obesity/overweight                                                   more than one third of the studies         None
  Significant improvement in conservatively managed group (*P*\<0.05)                                              
   DM/IGT                                                               None                                       None; significant worsening in one-quarter of the studies
   HTN                                                                  None; significant worsening in one study   None
   Dyslipidemia                                                         None                                       None; significant worsening in half of the studies
   Obesity/overweight                                                   None                                       None

Quality assessment and risk of bias {#sec2-4}
-----------------------------------

Most of the studies included in the systematic review were observational cohort studies, two were cross-sectional studies, and there was a single Randomized controlled trial (RCT). The methodological quality of the studies was therefore assessed using the NIH quality assessment tool for observational cohort and cross-sectional studies.\[[@ref15]\]

In view of inclusion of only a single RCT which was available on the review subject, it was suspected that the quality of evidence would be very low or poor. However, the assessment using the tool specifically designed for observational cohort and cross-sectional studies revealed that the quality of evidence was low to moderate or "fair" as per the NIH tool.

The risk of bias was mainly due to lack of confirmed presence of exposure prior to the outcomes; lack of sample size justification; heterogeneity between studies for diagnostic protocols, definitions of outcome and duration of follow-up; lack of blinded outcome assessments; and absence of adjustment for confounders. The results of quality assessment of individual studies as per NIH quality assessment tool are presented in [Table 8](#T8){ref-type="table"}.

###### 

Results of NIH quality assessment for observational cohort and cross-sectional studies

  Criteria                                                                                                                                                                                                                                      Yes                                                                                                                                                                                                                                                                                                                                         No                                                                                                                                                                                                                                                                                                                         Other (CD, NR, NA)\*
  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  1\. Was the research question or objective in this paper clearly stated?                                                                                                                                                                      Chiodini *et al*., Di Dalmazi *et al*., Erbil *et al*., Giordano *et al*., Iacoboe *et al*., Kim *et al*., Maehana *et al*., Miyazato *et al*., Morelli *et al*., Perysinakis *et al*., Petramala *et al*., Raffaelli *et al*., Sereg *et al*., Terzolo *et al*., Toniato *et al*., Tsuiki *et al*., Vassilatou *et al*.                    Kawate *et al*.                                                                                                                                                                                                                                                                                                            
  2\. Was the study population clearly specified and defined?                                                                                                                                                                                   Chiodini *et al*., Di Dalmazi *et al*., Erbil *et al*., Giordano *et al*., Iacobone *et al*., Kawate *et al*., Kim *et al*., Maehana *et al*., Miyazato *et al*., Morelli *et al*., Perysinakis *et al*., Petramala *et al*., Raffaelli *et al*., Sereg *et al*., Terzolo *et al*., Toniato *et al*., Tsuki *et al*., Vassilatou *et al*.                                                                                                                                                                                                                                                                                                                              
  3\. Was the participation rate of eligible persons at least 50%?                                                                                                                                                                              Chiodini *et al*., Di Dalmazi *et al*., Erbil *et al*., Giordano *et al*., Kawate *et al*., Kim *et al*., Maehana *et al*., Miyazato *et al*., Morelli *et al*., Perysinakis *et al*., Petramala *et al*., Raffaelli *et al*., Sereg *et al*., Terzolo *et al*., Toniato *et al*., Tsuiki *et al*., Vassilatou *et al*.                                                                                                                                                                                                                                                                                                                                                NR: Iacobone *et al*.
  4\. Were all the subjects selected or recruited from the same or similar populations (including the same time period)? Were inclusion and exclusion criteria for being in the study prespecified and applied uniformly to all participants?   Chiodini *et al*., Di Dalmazi *et al*., Erbil *et al*., Giordano *et al*., Iacobone *et al*., Kawate *et al*., Kim *et al*., Maehana *et al*., Miyazato *et al*., Morelli *et al*., Perysinakis *et al*., Petramala *et al*., Raffaell *et al*., Sereg *et al*., Terzolo *et al*., Toniato *et al*., Tsuiki *et al*., Vassilatou *et al*.                                                                                                                                                                                                                                                                                                                              
  5\. Was a sample size justification, power description, or variance and effect estimates provided?                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        Chiodini *et al*., Di Dalmazi *et al*., Erbil *et al*., Giordano *et al*., Iacobone *et al*., Kawate *et al*., Kim *et al*., Maehana *et al*., Miyazato *et al*., Morelli *et al*., Perysinakis *et al*., Petramala *et al*., Raffaelli *et al*., Sereg *et al*., Terzolo *et al*., Tsuiki *et al*., Vassilatou *et al*.   CD: Toniato *et al*.
  6\. For the analyses in this paper, were the exposure(s) of interest measured prior to the outcome(s) being measured?                                                                                                                         Chiodini *et al*., Erbil *et al*., Giordano *et al*., Iacobone *et al*., Kawate *et al*., Kim *et al*., Maehana *et al*., Miyazato *et al*., Morelli *et al*., Perysinakis *et al*., Petramala *et al*., Raffaelli *et al*., Sereg *et al*., Terzolo *et al*., Toniato *et al*., Tsuiki *et al*., Vassilatou *et al*.                                                                                                                                                                                                                                                                                                                                                  CD: Di Dalmazi *et al*.
  7\. Was the timeframe sufficient so that one could reasonably expect to see an association between exposure and outcome if it existed?                                                                                                        Di Dalmazi *et al*., Giordano *et al*., Iacobone *et al*., Kawate *et al*., Kim *et al*., Maehana *et al*., Miyazato *et al*., Morelli *et al*., Perysinakis *et al*., Raffaell *et al*., Sereg *et al*., Terzolo *et al*., Toniato *et al*., Vassilatou *et al*.                                                                           Chiodini *et al*., Erbil *et al*., Petramala *et al*., Tsuiki *et al*.                                                                                                                                                                                                                                                     
  8\. For exposures that can vary in amount or level, did the study examine different levels of the exposure as related to the outcome (e.g., categories of exposure, or exposure measured as continuous variable)?                             Morelli *et al*.(for CVE), Di Dalmazi *et al*.                                                                                                                                                                                                                                                                                              Chiodini *et al*., Erbil *et al*., Giordano *et al*., Iacobone *et al*., Kawate *et al*., Kim *et al*., Maehana *et al*., Miyazato *et al*., Perysinakis *et al*., Petramala *et al*., Raffaelli *et al*., Sereg *et al*., Terzolo *et al*., Toniato *et al*., Tsuiki *et al*., Vassilatou *et al*.                        
  9\. Were the exposure measures (independent variables) clearly defined, valid, reliable, and implemented consistently across all study participants?                                                                                          Chiodini *et al*., Di Dalmazi *et al*., Erbil *et al*., Giordano *et al*., Iacobone *et al*., Kawate *et al*., Kim *et al*., Maehana *et al*., Morelli *et al*., Perysinakis *et al*., Petramala *et al*., Raffaelli *et al*., Sereg *et al*., Terzolo *et al*., Toniato *et al*., Tsuiki *et al*., Vassilatou *et al*.                                                                                                                                                                                                                                                                                                                                                NR: Miyazato *et al*.
  10\. Was the exposure(s) assessed more than once over time?                                                                                                                                                                                   Chiodini *et al*., Giordano *et al*., Iacobone *et al*., Maehana *et al*., Morelli *et al*., Sereg *et al*., Toniato *et al*., Vassilatou *et al*.                                                                                                                                                                                          Erbil *et al*., Tsuiki *et al*.                                                                                                                                                                                                                                                                                            NR: Kawate *et al*., Miyazato *et al*., Perysinakis *et al*., Petramala *et al*., Raffaelli *et al*. NA: Di Dalmazi *et al*., Kim *et al*., Terzolo *et al*.
  11\. Were the outcome measures (dependent variables) clearly defined, valid, reliable, and implemented consistently across all study participants?                                                                                            Chiodini *et al*., Di Dalmazi *et al*., Erbil *et al*., Giordano *et al*., Iacobone *et al*., Kawate *et al*., Kim *et al*., Miyazato *et al*., Morelli *et al*., Perysinakis *et al*., Sereg *et al*., Toniato *et al*., Tsuiki *et al*.                                                                                                   Maehana *et al*., Petramala *et al*., Raffaelli *et al*., Terzolo *et al*., Vassilatou *et al*.                                                                                                                                                                                                                            
  12\. Were the outcome assessors blinded to the exposure status of participants?                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      NR: Chiodini *et al*., Erbil *et al*., Giordano *et al*., Iacobone *et al*., Kawate *et al*., Maehana *et al*., Miyazato *et al*., Perysinakis *et al*., Petramala *et al*., Morelli *et al*., Raffaelli *et al*., Sereg *et al*., Toniato *et al*., Tsuiki *et al*., Vassilatou *et al*. NA: Di Dalmazi *et al*., Kim *et al*., Terzolo *et al*.
  13\. Was loss to follow-up after baseline 20% or less?                                                                                                                                                                                        Chiodini *et al*., Erbil *et al*., Giordano *et al*., Iacobone *et al*., Kawate *et al*., Maehana *et al*., Miyazato *et al*., Morelli *et al*., Perysinakis *et al*., Petramala *et al*., Sereg *et al*., Toniato *et al*., Tsuiki *et al*., Vassilatou *et al*.                                                                           Raffaelli *et al*.                                                                                                                                                                                                                                                                                                         NA: Di Dalmazi *et al*., Kim *et al*., Terzolo *et al*.
  14\. Were key potential confounding variables measured and adjusted statistically for their impact on the relationship between exposure(s) and outcome(s)?                                                                                    Chiodini *et al*., Di Dalmazi *et al*., Morelli *et al*.                                                                                                                                                                                                                                                                                    Erbil *et al*., Giordano *et al*., Iacobone *et al*., Kawate *et al*., Kim *et al*., Maehana *et al*., Miyazato *et al*., Perysinakis *et al*., Petramala *et al*., Raffaelli *et al*., Sereg *et al*., Terzolo *et al*., Toniato *et al*., Tsuiki *et al*., Vassilatou *et al*.                                           

CD: Cannot determine, NA: Not applicable, NR: Not reported

D[ISCUSSION]{.smallcaps} {#sec1-4}
========================

Systematic review of studies with heterogeneous and limited published data suggest increased prevalence of components of metabolic syndrome in subclinical cortisol secreting and nonfunctioning AIs; a beneficial role of adrenalectomy on HTN, glucometabolic control, and BMI was observed in patients with subclinical cortisol secreting AIs.

For SCS, baseline prevalence of abnormal glucose metabolism ranged from 16.6% to 90%, HTN from 33 to 85%, high BMI from 25 to 80%, and dyslipidemia from 9 to 90% in the included studies. There were lesser number of studies on nonfunctioning AIs in the present review and the baseline prevalence of abnormal glucose metabolism ranged from 9% to 27%, HTN from 24% to 86%, high BMI from 27% to 63%, and dyslipidaemia from 5% to 60%. One study also looked into the prevalence of cardiovascular events and showed increased prevalence in patients with SCS\[[@ref20]\] and another study reported increased prevalence of coronary heart disease and stroke in SCS.\[[@ref17]\]

Studies assessing surgical outcome in SCS patients showed significant improvement in blood pressure from baseline in most of the studies, improvement in glucose metabolism in more than half, and improved BMI in more than a third of the studies. In the study by Petramala *et al*.,\[[@ref21]\] where outcome on metabolic syndrome (as per ATP III criteria)\[[@ref35]\] was studied, there was significant improvement in metabolic syndrome following adrenalectomy in SCS patients. For the conservatively managed SCS group, only a single study showed a significant worsening of HTN.

There was no significant improvement in any of the cardiometabolic parameters in patients with nonfunctioning AIs who underwent adrenalectomy. One study\[[@ref31]\] showed significant worsening in diabetes and dyslipidemia. For the conservatively managed patients with nonfunctioning AIs, follow-up data showed significant worsening of diabetes in a quarter of the included studies and worsening of dyslipidemia in half of them. There was no significant worsening of the other metabolic parameters in any of the studies.

The summary of results is presented in [Table 7](#T7){ref-type="table"}.

When the prevalence of cardiometabolic risk factors was compared between patients with nonfunctioning and subclinical cortisol secreting AIs, parameters of glucose metabolism and dyslipidemia were significantly worse for patients with SCS in most of the studies. However, there was no significant difference between the two groups for HTN and BMI. When the operated groups of nonfunctioning AI and SCS were compared in the study by Chiodini *et al*., there was significant improvement in diabetes, HTN, and obesity in surgically treated SCS patients.\[[@ref16]\] Comparison of prevalence of cardiometabolic risk factors between SCS and nonfunctioning AI is presented in [Table 6](#T6){ref-type="table"}.

The reason for a higher prevalence of cardiometabolic risk factors in patients with subclinical cortisol secreting AIs may be subtle or intermittent autonomous cortisol hypersecretion and the outcomes might have been related not only to the degree but also on the duration of hypersecretion, as well as the sensitivity of each individual to cortisol excess. As most patients with AIs are of an age when HTN, diabetes, and obesity are highly prevalent, establishing whether these metabolic complications are truly related to excess cortisol in a patient with an AI is not clear-cut.

Results from studies on outcomes of adrenalectomy have been conflicting but in general, the data indicated an improvement in metabolic complications, especially in blood pressure and diabetes, in patients with subclinical cortisol secreting AI after unilateral adrenalectomy, and deterioration or no improvement in patients treated conservatively. Five studies in the review directly compared the difference between surgical and medical outcomes and assessed changes in cardiovascular risk factors in the long term\[[@ref19][@ref21][@ref23][@ref24][@ref27]\] including one prospective randomized study.\[[@ref23]\] Petramala *et al*. also investigated metabolic syndrome (as per ATP III criteria)\[[@ref35]\] and the ambulatory BP (nondipper profile) and found a significant improvement in metabolic syndrome and nondipper profile in SCS group managed by adrenalectomy.\[[@ref21]\]

There is no consensus on management of SCS associated with AIs and one major issue is that there is no formal agreement as to its definition. The overnight low-dose DST is favored as the most sensitive screening test in patients with AI based on pathophysiological reasoning, simplicity, and the fact that the test was incorporated in the diagnostic algorithms of most studies.\[[@ref36]\] As patients lack the classical clinical features of Cushing\'s syndrome, it is difficult to determine the true value of the test. Diagnosing SCS by arbitrary cut-offs of cortisol secretion leads to unavoidable misclassifications in some patients. Therefore, additional tests in combination with the dexamethasone test are usually required to validate the biochemical diagnosis of hypercortisolism, although each has some limitations.

Increased prevalence of cardiometabolic risk factors was also observed in nonfunctioning AIs, although less than subclinical cortisol secreting AIs. It is speculated that the nonfunctioning AIs may not be entirely nonsecretory and may constitute an almost continuous spectrum of heterogeneous endocrine abnormalities. They may not produce adrenocortical hormones in sufficient amounts to cause clinically apparent disease or be detected biochemically, but they may have subtle qualitative alterations of steroidogenesis, which might adversely affect various metabolic pathways.\[[@ref37][@ref38]\]

The studies included in the current review did not reveal any significant impact of surgery on cardiometabolic morbidities in nonfunctioning AIs and there was significant worsening in diabetes and dyslipidemia in one study.\[[@ref31]\] Some studies on nonfunctioning AIs suggest improvement in parameters of metabolic syndrome after surgical treatment;\[[@ref11][@ref12][@ref39]\] however, they were not included in the review due to small number of operated patients. One of the likely explanations for this observation could be a potential misclassification of patients; for example, one study described that a significant proportion of patients with nonfunctioning AIs developed adrenal insufficiency after surgery, clearly suggesting that autonomous glucocorticoid production was not recognized preoperatively.\[[@ref39]\] Overall, glucocorticoid production has been linked to HTN, abnormal glucose tolerance, and increased BMI.\[[@ref40]\] Therefore, it is also possible that a temporary reduction of the glucocorticoid load caused by unilateral adrenalectomy could have contributed to a short-term improvement in blood pressure described in patients with nonfunctioning AIs.

Strengths and limitations {#sec2-5}
-------------------------

This systematic review has important strengths including an in-depth and comprehensive literature search, focused review questions, predefined inclusion and exclusion criteria, and use of standard quality assessment tool.

Limitations were heterogeneity in definitions of SCS in the studies with variable definitions of endpoints and outcomes and wide variations in length of follow-up. The length of time these metabolic risk factors were present was unknown. Groups also varied in the medical treatment for cardiovascular risk factors and it was unclear in the studies how aggressive the conservative management was in nonoperated patients. Subgroup analysis of age, gender, and size of the AI which might influence cardiovascular outcomes, was not possible, as individual variables were not consistently reported.

Future research directions {#sec2-6}
--------------------------

There is a clear need for prospective and appropriately powered studies to evaluate disease-specific and all-cause mortality and other hard clinical endpoints (i.e., myocardial infarction or stroke) to assess the potential cardiovascular morbidity associated with subclinical cortisol secreting AIs and nonfunctioning AIs and to substantiate whether surgical excision is beneficial in these patients. Such studies on subclinical cortisol secreting AI should also provide evidence for a suitable biochemical definition of autonomous cortisol secretion and help define the optimal investigation algorithm that balances the false-positive and negative endocrine test rates. Establishment of an international collaborative study group to develop a database of patients with clinically silent adrenal adenomas might be a useful step in this regard.

C[ONCLUSIONS]{.smallcaps} {#sec1-5}
=========================

Available low-to-moderate-quality evidence obtained from heterogeneous studies in this systematic review with at least 12 months of follow-up suggests increased prevalence of components of metabolic syndrome in patients with subclinical cortisol secreting and nonfunctioning AIs. Screening for independent cardiometabolic risk factors in patients with subclinical cortisol secreting AI is recommended and careful evaluation and long-term follow-up are required. Adrenalectomy might be considered for patients with mild hypercortisolism when medical treatment fails and there is progression of cardiovascular risks. Patients with subclinical cortisol secreting AI who are not candidates for surgery should be followed up clinically to detect, treat, and control cardiovascular risk factors. Until more data are available, a flexible approach guided by clinical judgment is recommended. Detailed endocrine workup of nonfunctioning AIs should include the evaluation of components of metabolic syndrome to identify patients at high cardiometabolic risk and appropriate lifestyle changes and medical treatment should be advised. Surgical intervention in the absence of hormonal excess is not recommended at present and is an area requiring further research.

Given the increasing prevalence of subclinical cortisol secreting and nonfunctioning AIs, their associated cardiometabolic morbidities and the controversies surrounding their management, there is a clear need for further studies and randomized controlled trials to guide future recommendations for therapy.
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